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Cost-EffECtivENEss of BENdamustiNE-RituximaB iN fiRst-LiNE 
iNdoLENt NHL: a PatiENt-LEvEL simuLatioN
Dewilde S.1, Woods B.2, Castaigne J.G.3, Parker C.2, Dunlop W.3
1SHE, Brussels, Belgium, 2Oxford Outcomes, Oxford, UK, 3Mundipharma International Limited, 
Cambridge, UK
Objectives: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) 
compared with standard of care as first-line treatment for patients with advanced 
indolent non-Hodgkin’s lymphoma (NHL) in England and Wales. MethOds: A 
patient-level simulation was adapted from the model used by the University of 
Sheffield School of Health and Related Research (ScHARR) in a health technology 
appraisal of rituximab for first-line treatment of follicular lymphoma (the most 
common type of indolent NHL). This approach allowed modelling of the complex 
treatment pathways in indolent NHL; specifically, first-line maintenance and sec-
ond-line treatment choice could be modelled as a function of patient age, and prior 
treatment choice and outcome. Data from a Phase 3 randomised, open-label trial 
by the Study group indolent Lymphomas (StiL) in Germany were used to compare 
B-R with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituxi-
mab). The relative efficacy of CHOP-R and CVP-R (cyclophosphamide, vincristine, 
prednisone, rituximab) was estimated as per the original ScHARR approach. The 
analysis was conducted from the perspective of the National Health Service, using 
a lifetime time horizon. One-way sensitivity and scenario analyses were conducted, 
including one using recently published randomised trial data comparing CVP-R with 
CHOP-R. Results: The base-case deterministic incremental cost-effectiveness ratio 
(ICER) was £5,249 per quality adjusted life year (QALY) for B-R vs. CHOP-R, and £8,092 
per QALY for B-R vs. CVP-R. The alternative scenario using direct data comparing 
CVP-R with CHOP-R more than halved the ICER for B-R vs. CVP-R to £3,468. Owing 
to its better toxicity profile, B-R reduced the cost of treating adverse events by over 
£1,000 per patient vs. CHOP-R. None of the one-way sensitivity or scenario analyses 
increased the ICER above £20,000. cOnclusiOns: The ICERs for B-R vs. CHOP-R and 
CVP-R were below the thresholds normally regarded as cost-effective in England 
and Wales (£20,000 – 30,000 per QALY).
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Cost-utiLity of GRaNuLoCytE-CoLoNy stimuLatiNG faCtoRs (G-Csfs) 
foR PRimaRy PRoPHyLaxis (PP) of CHEmotHERaPy iNduCEd fEBRiLE 
NEutRoPENia (fN) iN BREast CaNCER PatiENts iN tHE NEtHERLaNds
Somers L.1, Timmer-Bonte J.N.H.2, Gelderblom H.3
1OncoLogX bvba, Wuustwezel, Belgium, 2Alexander Monro Breast Cancer Hospital, Bilthoven, The 
Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands
Objectives: To assess number needed to treat to avoid an episode of FN (NNT) 
and cost-utility in The Netherlands of PP with once-per-cycle pegfilgrastim vs. no 
prophylaxis and vs. PP with daily G-CSF filgrastim (11-days as per label or 6-days 
suboptimal use) for reducing FN incidence in women with primary breast can-
cer receiving high risk chemotherapy for FN (e.g. TAC, a frequently used reference 
regimen in The Netherlands). MethOds: A decision-analytic model was con-
structed from health care-payer perspective. Costs were from official list prices 
(April 2013) or literature and included drugs, drug administration and FN-related 
medical costs and hospitalisations. Effectiveness inputs in terms of relative risk 
reduction (RRR) for FN were based on a recent meta-analysis. Survival and utility 
inputs were modeled from available data for breast cancer patients in the US and 
the UK. Outcomes included NNT and incremental cost effectiveness ratio (ICER) as 
cost per quality-adjusted life-year gained (QALY). Univariate sensitivity analyses 
evaluated the robustness of the model. Results: NNT with pegfilgrastim PP was 
lowest at 4.4, with filgrastim 11-days at 5.6 and filgrastim 6-days at 13.4. In terms 
of cost-utility, pegfilgrastim PP was dominant vs. 11-days filgrastim PP and was 
considered cost-effective vs. no prophylaxis (€ 29,896/QALY) and vs. PP with 6-days 
filgrastim (€ 7,615/QALY). In a scenario analysis reducing the prices of daily G-CSFs 
by 40%, pegfilgrastim PP remained cost-effective. The sensitivity analyses revealed 
that most sensitive variables were FN effectiveness (relative risk reductions), incre-
mental survival assumptions and cost of G-CSFs, and overall the model was robust 
to sensitivity analyses. cOnclusiOns: In a Dutch setting, pegfilgrastim PP offers 
a cost-effective approach to PP of FN. In the cost-utility analysis pegfilgrastim PP 
was dominant vs. 11-days filgrastim PP and cost-effective vs. no prophylaxis and 
6-days filgrastim PP.
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Cost-EffECtivENEss aNaLysis of aBiRatERoNE aCEtatE as sECoNd LiNE 
tREatmENt foR mEtastatiC CastRatioN-REsistaNt PRostatE CaNCER 
aftER doCEtaxEL tREatmENt iN JaPaN
Shibahara H.1, Shiroiwa T.2, Nakamura K.1, Shimozuma K.1
1Ritsumeikan University, Kusatsu, Japan, 2National Institute of Public Health, Saitama, Japan
Objectives: Abiraterone acetate improves overall survival of patients with meta-
static castration-resistant prostate cancer (CRCP). The NICE in the UK has recom-
mended abiraterone as a second line treatment for CRCP after docetaxel. Ministry 
of Health, Labour and Welfare (MHLW) has begun to discuss whether or how to use 
cost-effectiveness data for reimbursement or pricing. The purpose of this study is 
to evaluate cost-effectiveness of abiraterone plus prednisolone compared to pred-
nisolone alone in Japan. MethOds: Cost-effectiveness analysis was performed 
using a Markov model (TreeAge Pro 2013) based on data from the randomized control 
trial (COU-AA-301 study) and literature review conducted from the public health 
care payer’s perspective. The (1) abiraterone (1,000 mg once daily and orally) plus 
prednisolone (5 mg twice daily and orally) was compared with (2) prednisolone 
alone. The base case was assumed to be a 69 year-old man with metastatic CRPC. 
The model used a time horizon of 10 years. Outcomes were measured in quality-
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. MHLW has yet to approve abiraterone due to the delay in development, 
and drug cost was estimated based on prices in the UK and the US. Both cost and 
outcomes were discounted at a 2% annual rate based on Japanese guidelines for eco-
Objectives: To summarize the modeling methods used in published 
cost-effectiveness evaluations of first-line treatment for advanced NSCLC 
patients. MethOds: To identify relevant studies, a systematic literature search 
was performed in Medline®, EMBASE®, Medline-In-Process and the CRD data-
base from 2000 to 2013. In addition, Technology Appraisals (TA) were identified by 
searching the NICE, SMC and pCODR websites. Studies were included for review 
based on the following pre-defined criteria; 1) description of cost-effectiveness or 
cost-utility analysis; 2) inclusion of a comparison of drug interventions in first-line 
treatment of advanced NSCLC patients; and 3) results were expressed as cost per 
LY or QALY gained. Results: Out of 1009 unique citations, 21 publications and 
18 TA met the inclusion criteria. The identified cost-utility and cost-effectiveness 
analyses were all performed from a payer perspective for a variety of countries in 
Europe, Asia and North America. The economic value of targeted therapies for first-
line and maintenance treatment for advanced NSCLC patients were evaluated for 
different subpopulations according to histology type (non-squamous, squamous). 
The most commonly used modeling approach was the state-transition model 
with health states reflecting stable disease, progression, and death. Transitions 
between these health states were based on either fixed or time varying transition 
probabilities. Cost-effectiveness analyses that were based on a synthesis of clinical 
efficacy evidence primarily relied on the constant hazard ratio assumption. The 
impact of structural modeling assumptions on cost-effectiveness findings was 
frequently not reported. cOnclusiOns: Based on a review of published cost-
effectiveness evaluations, it was concluded that the rational for certain modeling 
choices are frequently not provided. In particular, choices pertaining to methods 
for clinical evidence synthesis and the impact on cost-effectiveness findings need 
to be justified in a more structured way.
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Cost-miNimizatioN aNaLysis (Cma) of diffERENt stRatEGiEs to tREat 
NEwLy diaGNosEd LoCaLLy CoNfiNEd Low-Risk PRostatE CaNCER 
(LCLRPC) iN GERmaNy: REsuLts of tHE HaRow study
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for the about 64,000 men diagnosed 
with prostate cancer each year in Germany still remains unclear. The objectives 
therefore were to estimate and compare costs under day-to-day conditions of car-
ing for men in Germany with newly diagnosed LCLRPC using hormonal therapy 
(HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watchful waiting 
(WW) – HAROW. MethOds: The long-term observational multi-centre HAROW 
study combined data collection from urologists (clinical data; utilized outpatient 
medical services, OMS) and from patients (employment status, QoL by EQ-5D, 
numerous health resource use items). Resource use was valued by year 2010 offi-
cial prices in € . Direct costs (DC) were given by hospital treatment, OMS and drugs, 
inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: sick leave, pre-
mature retirement, premature mortality) were estimated by 2010 gross domestic 
product/capita/day. Costs and quality-adjusted life-years (QALYs) were discounted 
by 3% per annum. Strategies without significant differences in QALYs/patient-year 
(PY) were compared by cost-minimization analysis (CMA) using mean costs/PY, 
remaining strategies by cost-utility analysis. Results: From 07/2008 to 03/2013, 
3063 LCLRPC patients (T1a–T2c, N0, M0; 67.3±7.5 years) were included from 257 
urologists: AS n= 452, RT n= 378, HT n= 210, HT+RT n= 80, combination therapy (CT) 
n= 137, OP n= 1647, other therapy (OT) n= 18, WW n= 141. Observation period: aver-
age 1.9 years, maximum 4.6 years. From the societal perspective (DC+IC), HT+RT 
had the lowest cost/PY (€ 1033), followed by AS (€ 1265), RT (€ 1313), WW (€ 1316), 
HT (€ 1522), CT (€ 3209), OT (€ 5705), and OP had highest cost/PY (€ 6656). From the 
perspective of DC, WW showed he lowest cost/PY (€ 894), followed by RT (€ 905), 
HT+RT (€ 987), AS (€ 1014), HT (€ 1169), OT (€ 2176), CT (€ 2204), and OP had highest 
cost/PY (€ 5374). cOnclusiOns: The HAROW study provides meaningful results 
on costs of different LCLRPC treatment strategies under day-to-day conditions of 
care in Germany to support decision making.
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HEaLtH tECHNoLoGy assEssmENt of CoNtRast-ENHaNCEd uLtRasouNd 
(CEus) tECHNiquEs
Dozsa C.1, Nagy J.2, Borcsek B.3
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The second generation of contrast-enhanced ultrasound (CEUS) techniques com-
bines the advantages of ultrasound techniques and the additional information 
provided by the contrast agent. Objectives: To prove that sulphur hexafluoride 
microbubbles contrast agent used for CEUS is as effective in detecting and ana-
lyzing abnormal-looking areas in the liver as currently used imaging techniques 
(contrast-enhanced CT and MRI: CECT and CEMRI), however the costs of CEUS are 
considerably lower. MethOds: Cost-minimization analysis was based on litera-
ture review (last 5 years MEDLINE research, evidence level 1++) and on Hungarian 
financing data. National medical protocols were also considered. Results: Average 
cost per patient of CEUS was 64,5 EUR, while costs of currently used techniques 
were 129 EUR. According to the literature 70% of currently used CT and MRI tech-
niques could be replaced by CEUS. Results made it evident that the equally effective 
contrast-enhanced ultrasound technique is more cost-effective than the currently 
used contrast-enhanced CT and MRI techniques. Health technology assessment 
suggested that the change for the new technology would save 64 509 million EUR 
for the National Health Insurance Fund at the end of the third year of application, 
counting with 5000 cases. cOnclusiOns: The widespread use of cost-effective 
CEUS technology is highly recommended as it is an evidently cost-saving technique 
from the insurer’s point of view. Further assessment is recommended to measure 
clinical parameters, burden of radiology and other quality of life parameters of 
patients, possibly by using a control group if this is ethically viable.
